ISM-001 is a potential first-in-class antibody that may lead to a new treatment pathway for patients with peripheral arterial ...

MINT Study Results Show Clinically Meaningful and Statistically Significant Efficacy in AChR+ and MuSK+ Patients ...

LEXINGTON, MA, USA and AMSTERDAM, The Netherlands I October 15, 2024 I uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population ...

LONDON, UK and CAMBRIDGE, MA, USA I October 15, 2024 I Beacon Therapeutics Holdings Limited ('Beacon Therapeutics' or 'the Company'), a leading ophthalmic ...

HAMBURG, Germany I October 15, 2024 I Topas Therapeutics today announced positive topline results from its Phase 2a trial evaluating lead candidate, TPM502, ...

ATLANTA, GA, USA I October 15, 2024 I Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle ...

REDMOND, WA, USA I October 14, 2024 I SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug ...

LONDON, UK I October 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, ...

CAMBRIDGE, MA, USA & MONTREAL, Canada I October 14, 2024 I Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage ...

NEW YORK, NY, USA I October 11, 2024 I Pfizer Inc. (NYSE: PFE)announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...

Approval is based on Phase III INAVO120 results, showing the ItovebiTM (inavolisib)-based regimen more than doubled progression-free survival compared with ...